What should I know about myOpportunITy?
We worked together with people living with ITP to ensure our studies measure and evaluate what matters, and to give you the best possible care throughout the study.
In the myOpportunITy 1 or myOpportunITy 2 study, you will receive subcutaneous infusions of either rozanolixizumab or placebo every two weeks. Twice as many people will receive rozanolixizumab than placebo, so your chances of receiving this potential new treatment are two in three. In total you will have approximately 30 visits across up to 34 weeks, some of which can be home visits.
For participants who have had their spleen removed, the study could be up to 44 weeks in total due to additional vaccination assessments during the screening period.
Rescue therapy is allowed at any time it is needed and will be free of charge. As a general rule, you can continue on the study if you receive rescue therapy. Depending on which medications you are taking at the time of screening, you may be allowed to continue taking some of them. Talk to your study physician about this and they will let you know which medications are permitted.
Home visits are where a nurse visits you in your home and performs the tests and assessments there without you having to travel to the study site. If you prefer, you can go to the study site for these visits instead. Your study doctor will also help to decide if home visits are appropriate for you.